TrialClinical drug investigation2026

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.

Andrew Ustianowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.